Yangtze River Pharmaceutical Group

What Yangtze River Pharmaceutical Group does

Yangtze River Pharmaceutical Group is a privately held, family-owned Chinese pharmaceutical manufacturer headquartered in Taizhou, Jiangsu Province, with operations spanning chemical drugs, traditional Chinese medicine (TCM), and consumer health products. The group's business is organized around three core brand matrices - Yangtze (扬子江) for Western medicine, Long Feng Tang (龙凤堂) for TCM, and Hu You (护佑) for health and wellness - plus the Lan Qin (蓝芩) throat health brand. Under the stewardship of Chairman, Party Secretary and President Xu Haoyu since the 2021 succession from founder Xu Jingren, the group operates more than 10 subsidiaries across Taizhou, Beijing, Shanghai, Nanjing, Guangzhou, Chengdu, Suzhou and Changzhou, four R&D bases staffed by a 1,000+ research team, and large-scale manufacturing campuses (for example, a 460+ acre Haici facility backed by RMB 1.7 billion of investment and a 344-acre Zilong subsidiary).

The company's offering spans multiple therapeutic areas, with cardiovascular, gastrointestinal, and respiratory products among its core franchises, supplemented by the Lan Qin throat health line and the newly launched 2026 innovative drug Tunotuo (盐酸妥诺达非片) in male health. Manufacturing and supply-chain operations are vertically integrated: more than 80 standardized TCM cultivation bases use IoT sensors and drone-based inspection to monitor raw material quality, while production lines run on an integrated enterprise and process control stack including SAP, OA, HR, SRM, CDS2, DMS, QMS, LIMS, SCADA, and DCS.

The firm generates revenue through a mixed B2B and B2C model: prescription pharmaceuticals are sold primarily through provincial and national tendering to medical institutions, OTC and consumer health products (notably the Lan Qin and Hu You ranges) are distributed through retail and consumer channels, and the firm is now expanding internationally, recording its first UK sale of injectable parecoxib in October 2025 following 2024 approvals in seven countries. A new growth vector is emerging around pharmaceutical and healthcare data, including the first public chronic-disease data transaction in Jiangsu Province (2025) and a multi-party initiative to build a Western Medical Data Elements Industry Hub. Quality and recognition signals include the EFQM Global Award (2021), the EFQM 7 Stars Certificate (2025), and China Quality Award nominations in 2018 and 2016.

Name

Yangtze River Pharmaceutical Group

Legal name

扬子江药业集团有限公司

Website

https://yangzijiang.com

Company type

Private

Founded year

1971

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Yangtze River Pharmaceutical Group is a privately held Chinese pharmaceutical manufacturer headquartered in Taizhou, Jiangsu, producing chemical drugs, traditional Chinese medicine, and consumer health products under the Yangtze, Long Feng Tang, Hu You, and Lan Qin brands for prescription, OTC, and international markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Pharmaceutical manufacturing
• Traditional Chinese medicine
• Chemical drug production
• Health product manufacturing
• Active pharmaceutical ingredients

Headquarters

HQ city

Taizhou

HQ country

China

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. 医药制造与销售: 集团主营业务为医药制造与销售，拥有多品牌、多元化的产品矩阵，包括化药、中药、大健康产品三大品类
2. 原料药生产与销售: 江苏海慈生物药业主要致力于高附加值原料药类和医药中间体的技术研究、生产和销售
3. CMO/CDMO业务: 江苏紫龙药业开展CMO业务，包括业务简介和CMO各模块选项
4. 创新药CDMO/CMO: 在创新药CDMO/CMO、药品代理销售等领域广泛开展对外合作

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Yangtze River Pharmaceutical Group manufactures and sells a diversified portfolio of chemical drugs (cardiovascular, anti-tumor, anti-infectives), traditional Chinese medicine preparations (tablets, capsules, granules, oral solutions, syrups, extracts covering 10 dosage forms), and big health consumer products (throat health, functional beverages, health foods) under three brand matrices. It also produces chemical active pharmaceutical ingredients (APIs) and offers CDMO/CMO services through its subsidiaries.

Product overview

Yangtze River Pharmaceutical Group operates as a comprehensive pharmaceutical enterprise with a multi-brand, diversified product portfolio spanning chemical drugs, traditional Chinese medicine (TCM), and health products. The group has established three main brand matrices: '扬子江' (Yangtze) for western medicines, '龙凤堂' (Long Feng Tang) for TCM products, and '护佑' (Hu You) for health and wellness offerings. The core product categories include chemical pharmaceutical preparations (化药), traditional Chinese medicine preparations (中药), and big health consumer products (大健康产品). Key products include the '蓝芩' (Lan Qin) throat health brand portfolio (oral liquid, throat candies, powders), flagship TCM products like '胃苏颗粒' and '荜铃胃痛颗粒', chemical drugs like enalapril and parecoxib, and innovative drugs such as the newly launched male health product '盐酸妥诺达非片（泰妥妥®）'. The group also produces APIs and intermediates through subsidiaries like Jiangsu Haici Bio-pharmaceutical.

Differentiator

Problem solved

Functional benefit

Brands

• 扬子江 (Yangtze): Western pharmaceutical brand of Yangtze River Pharmaceutical Group, covering chemical drug products.
• 龙凤堂 (Longfuantang)
• 护佑 (Huyou)
• 蓝芩 (Lanshen)

Products and services

• Chemical Drugs (化药) Western pharmaceutical products developed and manufactured by Yangtze River Pharmaceutical Group covering cardiovascular, anti-tumor, anti-infective and other therapeutic areas, sold to medical institutions and through distributors.
• Traditional Chinese Medicine (中药) Traditional Chinese medicine preparations produced by Jiangsu Pharmaceutical Co. covering 10 dosage forms (tablets, capsules, granules, oral solutions, syrups, electuaries, soft balms, teas, extracts) and 44 formulations leveraging TCM theories and herbal formulations.
• Big Health Products (大健康产品) Health and wellness products including dietary supplements, functional foods (over 30 health food approvals, 20+ health food products), and consumer goods developed under the 'Huyou' brand based on TCM 'treating the undiagnosed' and 'medicine-food homology' theories.
• Lan Qin (蓝芩) Throat Health Brand Portfolio Core brand covering throat health products including Lan Qin oral liquid, small Lan Qin oral liquid, Lan Qin powder, and Lan Qin throat candies (multiple flavors: mint, astragalus coffee, green tea, black tea, rose hip lemon, blueberry lollipop) — known as the 'Blue Container' product matrix for throat comfort.
• Wei Su Granules (胃苏颗粒) TCM formula for regulating qi and relieving stomach discomfort, a star TCM product of the group with annual sales reaching several hundred million yuan.
• Bi Ling Wei Tong Granules (荜铃胃痛颗粒) TCM formula promoting qi circulation and relieving blood stasis and stomach pain, recommended by medical experts in both TCM and Western medicine fields.
• Enalapril Maleate Tablets (依苏/马来酸依那普利片) Generic chemical drug for treating primary hypertension and renovascular hypertension, has passed bioequivalence evaluation.
• Parecoxib Sodium for Injection (注射用帕瑞昔布钠) Injectable COX-2 selective inhibitor for postoperative pain management; the group's first product to enter European high-regulation market with approvals in Netherlands, Australia, Malaysia, UK, and other countries.
• Active Pharmaceutical Ingredients (原料药) Chemical APIs produced by Jiangsu Haici Bio-pharmaceutical including Doxofylline, Raltitrexed, Levosimendan, Linagliptin, Propofol, Sugammadex Sodium, and other intermediates for domestic and international B2B customers.
• CDMO/CMO Services Contract development and manufacturing organization services offered by Jiangsu Zilong Pharmaceutical and Jiangsu Haici Bio-pharmaceutical, covering solid preparations, small-volume injections, lyophilized powder injections, transdermal patches, and external preparations for partner companies.
• Tunotuo (泰妥妥) - Tadalafil Hydrochloride Tablets Innovative male health drug (Tunotuo / 盐酸妥诺达非片) specifically developed for male health conditions, fully launched in June 2026.

Quantifiable outcome

• 品牌价值505.95亿元，医药健康板块第一
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• 江苏省首单公共数据产品交易（泰州市）coreStrategic or Co-development Partner · 1 January 20252025年企业作为采购方完成江苏省首单全过程公共数据产品场内交易，通过购买泰州市亚急性、慢性病数据集助力慢性咳嗽疾病的药物研制、现有药品的成效研究，为医药数据资产化探索了可行路径。
• 医疗机构与研究机构coreStrategic or Co-development Partner与华南理工大学、中山大学、暨南大学、浙江大学、中科院等国内知名科研院校开展产学研合作，成立仿制药、创新药、中药、生物药和医疗器械五大创新研发平台。
• 华南理工大学党委宣传部minorStrategic or Co-development Partner广州海瑞党支部联合华南理工大学党委宣传部、广东省江苏商会党支部开展文化宣传交流暨党建共建活动。
• 广东省江苏商会党支部minorStrategic or Co-development Partner广州海瑞党支部联合广东省江苏商会党支部开展文化宣传交流暨党建共建活动。
• 联和街社工站minorStrategic or Co-development Partner广州海瑞药业党支部与联和街社工站共同举办健康公益行活动，进行用药安全科普宣传和过期药品回收。
• 科学城总工会minorStrategic or Co-development Partner广州海瑞联合科学城总工会开展新年公益徒步活动。
• SANTISA (巴西)coreStrategic or Co-development Partner巴西知名制剂公司SANTISA CEO Mr.Dalton Durski一行莅临海瑞药业参访交流，就注射用帕瑞昔布钠产品的战略协作展开交流，在API/制剂出口、技术转移以及CMO/CDMO三大领域展开合作探讨。
• 中国银行minorStrategic or Co-development Partner广州海瑞党支部与中国银行开展共建交流活动。
• 广州科学城园区两新组织党委minorStrategic or Co-development Partner广州海瑞党支部与广州科学城园区两新组织党委携手开展义务植树活动。
• 广州市黄埔区市场监督管理局minorStrategic or Co-development Partner广州市黄埔区市场监督管理局岳霄霄总工程师、林生文主任前往海瑞药业开展党建及业务交流工作。
• 张太雷纪念馆minorStrategic or Co-development Partner江苏紫龙联合河北康佑赴张太雷纪念馆开展主题党日活动。

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Qilu Pharmaceutical (齐鲁制药): Large private Chinese generics and injectable manufacturer with strong API capabilities and growing international registrations. Comparable in scale, generics-and-injectables orientation, and CDMO aspirations.
• CR Sanjiu (华润三九): Leading China OTC and TCM brand owner (999 brand) with consumer-health focus. Comparable as a Chinese pharma that combines TCM heritage brands with OTC/health consumer products, similar to Yangtze's 龙凤堂 and 护佑 brands.
• CSPC Pharmaceutical Group (石药集团): Chinese pharma leader combining innovative drugs, generics, APIs and TCM. Comparable vertically integrated model with strong injectables portfolio and active international CDMO/export business.
• Guangzhou Pharmaceutical Holdings (广药集团): State-owned Chinese pharma with major TCM brands (Wanglaoji/CLP) and Western drug subsidiaries. Comparable as a vertically organized Chinese pharma combining TCM brands, chemical drugs and consumer health.
• Fosun Pharma (复星医药): Large Chinese pharmaceutical conglomerate with branded drugs, APIs, and significant international operations across regulated markets. Closely comparable to Yangtze in scale, multi-category portfolio (chemical drugs, biologics, diagnostics) and global expansion strategy.
• Tongrentang (同仁堂): Iconic Chinese TCM brand with branded TCM products and consumer-health extensions. Comparable as a Chinese TCM-rooted pharma with strong brand value and health-consumer crossover products.
• Sino Biopharmaceutical (中国生物制药): Major Hong Kong-listed Chinese pharma with hepatology, oncology, respiratory and pain franchises. Comparable scale, multi-therapeutic-area model and mix of branded chemical drugs plus TCM-adjacent products.
• Hayao Group (哈药集团): Major Chinese pharmaceutical manufacturer with branded chemical drugs, TCM, and OTC consumer health portfolio. Comparable as a privately-controlled Chinese pharma with multi-category brand matrix.
• Hengrui Pharma (恒瑞医药): China's largest innovative drug company with strong R&D pipeline in injectables, oncology and anesthesia (e.g., parecoxib class). Comparable as a Chinese pharma leader pivoting from generics to innovative drugs and pursuing international approvals.

Broad incumbents

• Bayer AG: Global pharmaceutical incumbent with significant Chinese market presence, particularly in women's health, cardiology and OTC. Comparable as a broader pharma operating in similar therapeutic areas with China-market exposure, but at a much larger global scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/yangtzeriverpharmaceuticalgrouppharmaceuticalcoltd.

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yangtze River Pharmaceutical Group